Skip to content
Peptide research

Melanotan II

Also known as MT-II
Category
Skin & Cosmetic
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A cyclic analog of alpha-MSH that activates the melanocortin receptors, sold for tanning, erectile function, and appetite suppression. Human evidence is good for erections and tanning but weak for appetite and sun protection. Most users get nausea and flushing, and the real concern is that it stimulates melanocytes with a possible melanoma link, plus case reports of rhabdomyolysis and priapism. It is not an approved US drug, and the FDA warns against it.

Read Full record

Studied uses & evidence

Studied uses(5)

  • Skin tanning

    Medium

    MC1R activation drives eumelanin; visible darkening after 5 injected doses, strongest in fair skin.

  • Erectile function

    High

    In a small human trial, 17 of 20 men with erectile dysfunction achieved erection without stimulation.

  • Sexual desire/arousal

    Medium

    Small controlled studies found increased desire in men; MT-II research later led to PT-141.

Evidence limits

Evidence Level
Early Clinical (Phase I/II)

Phase I (Dorr 1996, n=3): tanning confirmed. Double-blind RCT (Wessells 2000, n=20): potent erectile effects. Never advanced to Phase III. Derivative PT-141 completed full development. Case reports of serious AEs (rhabdomyolysis, renal infarction, melanoma association).

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • History of melanoma or dysplastic nevi

    Absolute

    Stimulates melanocyte activity. Can darken existing moles and may promote melanoma in predisposed individuals.

  • Autoimmune skin conditions

    Moderate

    Melanocyte stimulation may worsen autoimmune skin conditions like vitiligo.

  • Cardiovascular disease

    Moderate

    Can increase blood pressure and heart rate through melanocortin receptor activation.

General cautions

  • Pregnancy

    Absolute

    No safety data. Affects multiple hormone systems.

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • NOT FDA-approved; FDA explicitly warns against use

    High
  • Rhabdomyolysis (case reports)

    Moderate
  • Renal infarction (case report)

    Low
  • Possible melanoma association; stimulates melanocyte proliferation

    Moderate
  • Nausea, facial flushing in most users

    High
  • Priapism (prolonged painful erection)

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.